Spyre Therapeutics, Inc. (SYRE) Financial Statements
Spyre Therapeutics, Inc. (SYRE) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$178.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$208.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SYRESpyre Therapeutics, Inc.Follow SYRE — free
—
Price chart with a free account
- Market cap
- 8.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | — | |
| Research & development | 0.02 | 0.02 | 0.04 | 0.06 | 0.06 | 0.06 | 0.06 | 0.09 | 0.16 | 0.17 | 0.22 | |
| Operating income | -0.02 | -0.03 | -0.05 | -0.08 | -0.08 | -0.07 | -0.08 | -0.24 | -0.21 | -0.21 | -0.20 | |
| Pre-tax income | -0.02 | -0.03 | -0.04 | -0.08 | -0.08 | -0.07 | -0.08 | -0.34 | -0.21 | -0.16 | -0.18 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 | -0.00 | 0.00 | |
| Net income | -0.02 | -0.03 | -0.04 | -0.08 | -0.08 | -0.07 | -0.08 | -0.34 | -0.21 | -0.16 | -0.18 | |
| Diluted EPS ($) | — | -1.80 | -2.13 | -2.45 | -1.52 | -1.00 | -24.86 | 13.76 | — | — | — | |
| Diluted shares (bn) | — | — | — | — | — | — | 0.003 | 0.007 | — | — | — |
USD billions · SEC XBRL
Spyre Therapeutics, Inc. — questions
- What is Spyre Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Spyre Therapeutics, Inc.'s net income?
- -$178.9M over the twelve months to 2026-06-30.
- What is Spyre Therapeutics, Inc.'s free cash flow?
- -$208.9M over the twelve months to 2026-06-30.
Every figure on this page comes from Spyre Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.